Outcomes for Patients with Generalized Myasthenia Gravis Prescribed Ravulizumab or Efgartigimod Treatment: A Retrospective Medical Record Analysis (P1-11.001)
Evaluate outcomes among patients with generalized myasthenia gravis (gMG) treated with ravulizumab or efgartigimod as first targeted immunotherapy.
Authors
- Prathamesh Pathak (ORCID: https://orcid.org/0009-0003-6107-4185)
- Danielle Gentile
- Samir Macwan
- Karen W L Yee (ORCID: https://orcid.org/0000-0002-2572-9952)
- Jason Arthur Sharpe (ORCID: https://orcid.org/0000-0002-3506-2979)
- Christopher A. Scheiner
- Michael Pulley (ORCID: https://orcid.org/0000-0003-1879-725X)
- Michael Blackowicz (ORCID: https://orcid.org/0000-0003-0815-3178)
- Chloe Sader
- Nana Numapau
- Nicholas Streicher
Institutions
- Georgetown University (US)
- University of Tennessee Medical Center (US)
- MedStar Georgetown University Hospital (US)
- University of Florida (US)
- AstraZeneca (Brazil) (BR)
- Cardinal Health (United States) (US)
- Alexion Pharma (Switzerland) (CH)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208765
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78